Showing results (81-90 of 176) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid TumorsEmiliano Calvo, Jean-Charles Soria, Wen Wee Ma, et al.
The Oncologist|September 24, 2025
Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trialSarina A Piha-Paul, Justin A Call, Alexander I Spira, et al.
Pharmacology Research & Perspectives|June 23, 2020
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairmentKarthick Vishwanathan, Inmaculada Sanchez-Simon, Bhumsuk Keam, et al.
Investigational New Drugs|April 24, 2015
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancerAnalia Azaro, Jordi Rodon, Antonio Calles, et al.
American Journal of Clinical Oncology|June 1, 2004
Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Emiliano Calvo, et al.
Journal for Immunotherapy of Cancer|September 20, 2017
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resectionRocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, et al.
Oncology|November 29, 2002
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Jose Manuel Aramendia, et al.
Cardiology Journal|January 2, 2023
Measurement of vegetations in infective endocarditis: An inaccurate method to decide the therapeutical approachGonzalo Cabezón Villalba, Javier López, Pablo Elpidio Garcia-Granja, et al.
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Pageof 18